In addition, some studies report the usefulness of NfL in MS treatment follow-up, as nataliumab, ocrelizumab, rituximab, mitoxantron, and fingolimod were found to decrease the NfL levels [34,36,37,38,39,40,41,42,43]. Here, NEFL is linked to myeloid sarcoma.